Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration‐resistant prostate cancer
Abstract
Docetaxel prednisone is a standard of care for men with metastatic castration‐resistant prostate cancer (mCRPC), and plasma vascular endothelial growth factor (VEGF) levels are a poor prognostic factor in this population; therefore, we evaluated the combination of docetaxel prednisone with pazopanib, an oral VEGF receptor inhibitor, for safety and preliminary efficacy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 09, 2019
- Source ID
- 10.1002/pros.23899
Entities
People
- Andrew B Nixon
- Andrew J. Armstrong
- Carolyn Winters
- Daniel J George
- Elia Martinez
- Ian Barak
- Melissa Klein
- Michael R. Harrison
- Monika Anand
- Patrick Healy
- Rhonda Wilder
- Russell Szmulewitz
- Susan Halabi
Organizations
- Duke University
- United States Department of Defense
- University of Chicago